Abbott's AFib breakthroughs show 84% success with Volt PFA and TactiFlex Duo

Abbott's AFib breakthroughs show 84% success with Volt PFA and TactiFlex Duo

Mitchell Wilson
Mitchell Wilson
2 Min.
An old book with a red cross and a plus symbol on the cover, likely a first-aid kit, with text written on it.

Abbott's AFib breakthroughs show 84% success with Volt PFA and TactiFlex Duo

Abbott has unveiled new clinical findings on its minimally invasive treatments for atrial fibrillation (AFib) at the AF Symposium in Boston. The results highlight strong performance from two key devices: the Volt PFA System and the TactiFlex Duo Ablation Catheter. Both therapies showed significant improvements in patient outcomes and quality of life.

The Volt PFA System received both FDA approval and CE Mark certification, allowing commercial use in the US and expanded rollout across Europe. Clinical trials reported an 84.2% success rate for treating Paroxysmal AFib (PAF) and a 67.7% success rate for Persistent AFib (PersAF) after 12 months. Patients also required fewer therapy applications—an average of 4.6 per vein—compared to competing systems. Only 5.8% of those treated needed a repeat procedure, and quality-of-life scores jumped from 63.6 to 91.4 for PAF patients and from 64.2 to 91.4 for PersAF patients.

The TactiFlex Duo Ablation Catheter, designed for focal ablation with a dual-energy platform, achieved an 81% success rate in treating PAF at six months in the FOCALFLEX Global CE Mark trial. This device allows physicians to adjust therapy based on individual patient needs and anatomy. Quality-of-life scores for patients using this catheter improved from 64.4 to 86.4 following treatment.

Abbott will also present late-breaking data on its Amulet device on Friday, February 6, between 5:30 and 7 p.m. Eastern. The findings come from the VERITAS Amulet 360 Pivotal Study, adding to the company's growing body of research in AFib treatment. As of early 2026, the Volt PFA System study has enrolled data from 45 medical centres worldwide, including sites in Japan, Australia, and the Middle East.

The latest results confirm the Volt PFA System's regulatory approval and commercial launch in key markets. Both it and the TactiFlex Duo Ablation Catheter have demonstrated high success rates, fewer repeat procedures, and marked improvements in patient well-being. Abbott's upcoming presentation on the Amulet device will provide further insights into its expanding AFib treatment portfolio.

Neueste Nachrichten